First-in-human Study of SRF388, a First-in-class IL-27 Targeting Antibody, As Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid TumorsAung Naing,Charlene Mantia,Daniel Morgensztern,Tae-Yong Kim,Daneng Li,Yoon-Koo Kang,Thomas Urban Marron,Abhishek Tripathi,Saby George,Brian I. Rini,Anthony B. El-Khoueiry,Ulka N. Vaishampayan,Robin Kate Kelley,Moshe Chaim Ornstein,Leonard Joseph Appleman,Lauren C. Harshman,Benjamin Lee,Nizar M. Tannir,Hans J. Hammers,Amita PatnaikJOURNAL OF CLINICAL ONCOLOGY（2022）引用 7|浏览26AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
